Rapt Therapeutics (RAPT) Competitors $13.49 +0.76 (+5.97%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. DNA, DAWN, TBPH, PROK, GHRS, ABUS, KURA, KALV, TYRA, and IMTXShould you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Ginkgo Bioworks (DNA), Day One Biopharmaceuticals (DAWN), Theravance Biopharma (TBPH), ProKidney (PROK), GH Research (GHRS), Arbutus Biopharma (ABUS), Kura Oncology (KURA), KalVista Pharmaceuticals (KALV), Tyra Biosciences (TYRA), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Rapt Therapeutics vs. Its Competitors Ginkgo Bioworks Day One Biopharmaceuticals Theravance Biopharma ProKidney GH Research Arbutus Biopharma Kura Oncology KalVista Pharmaceuticals Tyra Biosciences Immatics Rapt Therapeutics (NASDAQ:RAPT) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Does the media favor RAPT or DNA? In the previous week, Ginkgo Bioworks had 8 more articles in the media than Rapt Therapeutics. MarketBeat recorded 8 mentions for Ginkgo Bioworks and 0 mentions for Rapt Therapeutics. Ginkgo Bioworks' average media sentiment score of 0.61 beat Rapt Therapeutics' score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Overall Sentiment Rapt Therapeutics Neutral Ginkgo Bioworks Positive Which has higher valuation & earnings, RAPT or DNA? Rapt Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Rapt Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapt Therapeutics$1.53M145.88-$129.87M-$14.17-0.95Ginkgo Bioworks$227.04M2.83-$547.03M-$5.86-1.85 Which has more risk & volatility, RAPT or DNA? Rapt Therapeutics has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Do institutionals and insiders have more ownership in RAPT or DNA? 99.1% of Rapt Therapeutics shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 2.4% of Rapt Therapeutics shares are owned by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer RAPT or DNA? Rapt Therapeutics presently has a consensus target price of $21.57, suggesting a potential upside of 59.86%. Ginkgo Bioworks has a consensus target price of $9.50, suggesting a potential downside of 12.33%. Given Rapt Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Rapt Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapt Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is RAPT or DNA more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -136.56%. Ginkgo Bioworks' return on equity of -43.25% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapt TherapeuticsN/A -67.92% -59.59% Ginkgo Bioworks -136.56%-43.25%-22.29% SummaryRapt Therapeutics and Ginkgo Bioworks tied by winning 8 of the 16 factors compared between the two stocks. Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$223.19M$3.15B$5.77B$9.87BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-0.9521.0975.6126.46Price / Sales145.88471.78551.64120.26Price / CashN/A45.1137.1158.92Price / Book1.179.7711.536.02Net Income-$129.87M-$53.47M$3.29B$266.38M7 Day Performance18.58%0.91%-0.12%-0.53%1 Month Performance33.60%6.59%6.12%3.30%1 Year Performance-12.60%11.62%60.95%22.81% Rapt Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRapt Therapeutics3.5628 of 5 stars$13.49+6.0%$21.57+59.9%-22.0%$223.19M$1.53M-0.9580DNAGinkgo Bioworks1.4436 of 5 stars$12.06-3.9%$9.50-21.2%+86.8%$713.95M$227.04M-2.06640News CoverageGap DownDAWNDay One Biopharmaceuticals2.3509 of 5 stars$6.97-3.2%$25.29+262.8%-46.7%$713.94M$131.16M-7.3460Positive NewsTBPHTheravance Biopharma3.6642 of 5 stars$13.80-0.8%$21.33+54.6%+74.8%$694.98M$77.21M57.50110Trending NewsAnalyst RevisionHigh Trading VolumePROKProKidney3.396 of 5 stars$2.35-2.5%$6.25+166.0%+5.5%$691.56M$80K-4.123GHRSGH Research2.2518 of 5 stars$13.18+0.8%$32.00+142.8%+65.9%$685.76MN/A-17.8110News CoverageABUSArbutus Biopharma1.7201 of 5 stars$3.50-2.5%$5.50+57.1%-2.0%$670.95M$15.42M-12.0790News CoveragePositive NewsKURAKura Oncology3.8418 of 5 stars$7.65flat$24.10+215.0%-59.0%$664.00M$83.28M-3.38130News CoveragePositive NewsAnalyst ForecastKALVKalVista Pharmaceuticals4.0542 of 5 stars$12.99-3.1%$26.29+102.4%+17.6%$648.90MN/A-3.52100News CoverageUpcoming EarningsTYRATyra Biosciences2.7256 of 5 stars$12.00+2.5%$30.83+156.9%-43.0%$639.60MN/A-6.7420News CoveragePositive NewsAnalyst ForecastIMTXImmatics2.4249 of 5 stars$5.23-8.1%$14.67+180.4%-49.1%$635.71M$168.65M-8.05260News CoveragePositive News Related Companies and Tools Related Companies Ginkgo Bioworks Competitors Day One Biopharmaceuticals Competitors Theravance Biopharma Competitors ProKidney Competitors GH Research Competitors Arbutus Biopharma Competitors Kura Oncology Competitors KalVista Pharmaceuticals Competitors Tyra Biosciences Competitors Immatics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPT Stock Alerts